Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 5:26 PM
Ignite Modification Date:
2025-12-24 @ 5:26 PM
NCT ID:
NCT06691568
Brief Summary:
The goal of this clinical trial is to evaluate the efficacy of air purifiers in reducing allergy symptoms in patients with a cat allergy. The main question it aims to answer is:
If there is a reduction of early asthmatic response (EAR) compared to placebo.
Participants were asked to remain in an exposure chamber for 2 hours while their symptoms were monitored.
Detailed Description:
For this protocol, 30 patients with cat allergies were exposed to 80ng/m3 of Fel d 1 allergen in the ALYATEC Environmental Exposure Chamber (EEC).
The active group of 15 had Dyson BP06 air purifiers running at speed 2, while the placebo group had the purifiers on, but not circulating air (speed 0). Participants were monitored for the primary objective of reduction of EAR, alongside other secondary objectives:
1. To evaluate the efficacy of air purifier on time to induce EAR during a 2-hour cat allergen exposure in ALYATEC EEC compared to placebo
2. To evaluate the efficacy of air purifier on allergic rhino-conjunctivitis symptoms during a 2-hour cat allergen exposure in ALYATEC EEC compared to a placebo
3. To evaluate the efficacy of air purifier on bronchial response severity during a 2-hour cat allergen exposure in ALYATEC EEC compared to placebo.
4. To evaluate the rescue treatments used after 2-hour cat allergen exposure with the air purifier compared to placebo
5. To evaluate the efficacy of air purifier on allergic rhinitis symptoms during a 2-hour cat allergen exposure in ALYATEC EEC compared to a placebo
Study:
NCT06691568
Study Brief:
Protocol Section:
NCT06691568